Findings

What do systematic reviews say?

4 questions · 4 findings · 3 reviews · Gut

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 25%Low 3 · 75%Moderate 0 · 0%High 0 · 0%

Withdrawals due to adverse events · inactive EoE patients

Corticosteroids may leads to lower withdrawals due to adverse events 12 to 50 weeks compared with placebo (low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 0.37 [0.16, 0.87]
3 studies · 280 participants
Low

Withdrawals due to adverse events · active EoE patients

Corticosteroids may leads to lower withdrawals due to adverse events (2 to 12 weeks) compared with placebo (low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 0.64 [0.43, 0.96]
14 studies · 1032 participants
Low

Withdrawals due to adverse events · induction of remission in Crohn's disease

It is very uncertain whether enteral nutrition changes withdrawal due to adverse events compared with corticosteroids (very low certainty).

1 finding from 1 review

Enteral nutritional therapy for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
RR 2.95 [1.02, 8.48]
3 studies · 169 participants
Very low

Withdrawals due to adverse events · Patients with active Crohn's disease

Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with conventional steroids (low certainty).

1 finding from 1 review

Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 0.57 [0.18, 1.84]
5 studies · 522 participants
Low